Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

NovaGo Therapeutics secures USD 30 million in Series B financing led by Neurimmune and Pureos to advance a proof-of-concept study for acute spinal cord injury.

PRIVATESep 02, 2026•6 days ago

Amount Raised

$30 Million

Round Type

Series B

ZurichBiotechnologyHealth CareTherapeutics

Investors

PureosNeurimmune

Description

NovaGo Therapeutics announced the completion of a CHF 24 million (USD 30 million) Series B financing round, led by Neurimmune and Pureos. The funding will be utilized to advance its lead program into a proof-of-concept study in patients with acute spinal cord injury. This study is designed to enroll 120 patients across sites in Germany, Spain, and Switzerland. The financing round also includes contributions from existing and new investors, complemented by non-dilutive funding from two foundations.

Company Information

Company

NovaGo Therapeutics

Location

Zurich, Switzerland

About

NovaGo Therapeutics AG is a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system. The company's lead program aims to advance to a proof-of-concept study in patients with acute spinal cord injury. NovaGo focuses on addressing the high unmet medical needs in spinal cord injury with innovative therapeutic solutions.

Don't miss NovaGo Therapeutics's next move

Get an email the moment NovaGo Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for NovaGo Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

NovaGo Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.